Pamela Dickson Harris

US Patent:

D456708, May 7, 2002

Filed:

May 22, 2001

Appl. No.:

29/142230

Inventors:

Pamela Harris - Riverdale GA 30274

International Classification:

0903

US Classification:

D 9338

US Patent:

20090298097, Dec 3, 2009

Filed:

Jul 17, 2008

Appl. No.:

12/175451

Inventors:

Pamela J. Harris - Bethesda MD, US
Michael S. Lebowitz - Baltimore MD, US
Hossein A. Ghanbari - Potomac MD, US

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The present invention is directed to new ways to diagnosis lung cancer, especially at an early clinical stage. In addition, prognosis and the monitoring of therapeutic agents or other treatments, for lung cancer patients, can be accomplished with the disclosed methods. The methods also find use in allowing the assessment by pre-clinical animal efficacy studies to screen for the useful of therapeutic agents for treating lung cancer.

US Patent:

57007810, Dec 23, 1997

Filed:

Nov 10, 1994

Appl. No.:

8/338166

Inventors:

Pamela Jo Harris - Washington DC

International Classification:

A61K 3800
A61K 3921
C07K 100

US Classification:

514 21

Abstract:

Prophylaxis against HIV, treatment for individuals infected with HIV, and treatment Kaposi's sarcoma can be effected, respectively, through the administration of human chorionic gonadotropin.

US Patent:

58519971, Dec 22, 1998

Filed:

Jul 2, 1996

Appl. No.:

8/676518

Inventors:

Pamela Jo Harris - Washington DC

International Classification:

A61K 3800
A61K 3921
C07K 100

US Classification:

514 21

Abstract:

Prophylaxis against viral infections, as well as treatment for individuals infected with a virus, can be achieved through the administration of human chorionic gonadotropin (HCG). Exemplary of the viral infections that are amenable to the use of HCG in this regard include those caused by HIV-1, Kaposi's sarcoma herpes virus, molluscipoxvirus and cytomegalovirus. In addition, HCG can be used as a neonatal immune booster via administration to a baby at delivery and, optionally, for the first several months of life, until the infantile immune system matures, in order to prevent HIV transmission and control any low-level viremia, as well as to protect against various other viruses, such as herpes viruses and oncogenic viruses.